Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Anal high-grade squamous intraepithelial lesions (precursor), drawn from the whole corpus: 1 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Most HSIL never progresses, and no marker yet says which lesions to treat and which to watch.
High-resolution anoscopy is scarce outside specialist centres.
Recurrence after ablation is common and the best retreatment strategy is untested.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Treatment journeys · Survivorship planner.
Whether screening helps people at high risk who do not have HIV is unproven.
Nothing recorded yet.
Also on OnCo: Symptoms and red flags · Early detection roadmap.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 6 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
Progression to anal cancer 173 per 100,000 person-years with treatment against 402 with active monitoring, a 57 percent reduction (95% CI 6 to 80, p 0.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.